

B1  
cmcll.

154. (New) The pharmaceutical composition according to claim 153, wherein said substance is a monoclonal antibody reactive to CTGF.

### REMARKS

Claims 104-154 are now pending in this application. The newly added claims 104-154 are supported in originally pending, now canceled claims 1-82.

No new matter has been added.

In the event any fees are due in connection with the filing of this preliminary amendment or attached application or if petitions are required, applicants petition for any required relief and authorize the Commissioner to charge the cost of such petitions or other fees to our Deposit Account No. 50-0815.

Respectfully submitted,  
BOZICEVIC, FIELD & FRANCIS LLP

Date: Sept 5, 2000

By: Karl Bozicevic

Karl Bozicevic  
Registration No. 28,807

BOZICEVIC, FIELD & FRANCIS LLP  
200 Middlefield Road, Suite 200  
Menlo Park, CA 94025  
Telephone: (650) 327-3400  
Facsimile: (650) 327-3231